Literature DB >> 1677699

Immune response to intradermally injected inactivated poliovirus vaccine.

B U Samuel1, T Cherian, G Sridharan, P Mukundan, T J John.   

Abstract

Immune response to intradermal inoculation of a fractional dose of inactivated poliovirus vaccine (IPV) was measured in 8 adults and 10 children who were previously immune. A striking 4-fold to 1024-fold antibody booster response to all 3 poliovirus serotypes was found in 15 subjects and a similar response to 2 poliovirus serotypes occurred in the other 3 children. Induration and erythema of 3 mm diameter or above, indicative of a cell-mediated immune response, was seen in 12 subjects. Intradermal inoculation of IPV may be a useful technique for secondary immunisation programmes against polio and its use for primary immunisation merits investigation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677699     DOI: 10.1016/0140-6736(91)90480-d

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.

Authors:  Yotam Levin; Efrat Kochba; Ivan Hung; Richard Kenney
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.

Authors:  Stephanie B Troy; Diana Kouiavskaia; Julia Siik; Efrat Kochba; Hind Beydoun; Olga Mirochnitchenko; Yotam Levin; Nancy Khardori; Konstantin Chumakov; Yvonne Maldonado
Journal:  J Infect Dis       Date:  2015-01-07       Impact factor: 5.226

3.  Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.

Authors:  Cynthia J Snider; Khalequ Zaman; Concepcion F Estivariz; Mohammad Yunus; William C Weldon; Kathleen A Wannemuehler; M Steven Oberste; Mark A Pallansch; Steven Gf Wassilak; Tajul Islam A Bari; Abhijeet Anand
Journal:  Lancet       Date:  2019-05-16       Impact factor: 79.321

Review 4.  Delivery systems for intradermal vaccination.

Authors:  Y C Kim; C Jarrahian; D Zehrung; S Mitragotri; M R Prausnitz
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 5.  Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system.

Authors:  Giancarlo Icardi; Andrea Orsi; Antonella Ceravolo; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2012-01-01       Impact factor: 3.452

6.  Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization.

Authors:  Hiromasa Okayasu; Carolyn Sein; Diana Chang Blanc; Alejandro Ramirez Gonzalez; Darin Zehrung; Courtney Jarrahian; Grace Macklin; Roland W Sutter
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

7.  Development of a thermostable microneedle patch for polio vaccination.

Authors:  Chandana Kolluru; Yasmine Gomaa; Mark R Prausnitz
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

8.  Role of innate lymphoid cells and dendritic cells in intradermal immunization of the enterovirus antigen.

Authors:  Shengtao Fan; Yun Liao; Yaru Lian; Guorun Jiang; Li Jiang; Chenhong Dong; Erxia Yang; Lichun Wang; Xingli Xu; Min Feng; Ying Zhang; Qihan Li
Journal:  NPJ Vaccines       Date:  2019-03-27       Impact factor: 7.344

Review 9.  Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Authors:  Edward Pk Parker; Natalie A Molodecky; Margarita Pons-Salort; Kathleen M O'Reilly; Nicholas C Grassly
Journal:  Expert Rev Vaccines       Date:  2015-07-09       Impact factor: 5.217

Review 10.  Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status.

Authors:  T Jacob John; Vipin M Vashishtha
Journal:  Indian J Med Res       Date:  2013-05       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.